Cart
sales@molnova.com
Demcizumab
CAS No. 1243262-17-0
Demcizumab( —— )
Catalog No. M36721 CAS No. 1243262-17-0
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 886 | In Stock |
|
| 10MG | 1416 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDemcizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionDemcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.
-
DescriptionDemcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
-
In VitroCell Viability AssayCell Line:PDTALL13 (patient-derived T-ALL 13) cell Concentration:0, 0.5, 1, 5, 10, 20, 40, 80 μg/mL Incubation Time:1 or 2 or 3 days Result:Dose-dependently inhibited cell viability.
-
In VivoAnimal Model:KRASWT and KRASMT CRC xenografts Dosage:10 mg/kg, together with Irinotecan (HY-16562) (7.5 mg/kg) Administration:Intraperitoneal injection (i.p.), once a week Result:Resulted in tumor regression at day 20.
-
Synonyms——
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorGamma-secretase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1243262-17-0
-
Formula Weight145.65 (kDa)
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. ?
molnova catalog
related products
-
PEAQX
PEAQX(NVP-AAM 077) is an effective and orally available NMDA antagonist. It can inhibit human NMDA receptors for 1A/2A(IC50: 270 nM), rather than 1A/2B(29, 600 nM).
-
MN-64
MN-64 is a tankyrases inhibitor, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.
-
YO-01027
YO-01027 (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM for APPL and Notch cleavage, respectively.
